On December 21, 2023, Mercer Street Global Opportunity Fund, LLC filed a Schedule 13G with the SEC, disclosing a significant stake in Biodexa Pharmaceuticals PLC. The fund reported ownership of 109,396,800 Ordinary Shares, which includes 46,900,000 shares issuable upon the exercise of warrants, representing a 9.99% ownership in the company. This stake is subject to a beneficial ownership blocker, preventing the fund from exercising warrants that would result in ownership exceeding 9.99% of Biodexa's outstanding Ordinary Shares. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Biodexa Pharmaceuticals. Jonathan Juchno, an authorized representative of Mercer Street Global Opportunity Fund, LLC, has disclaimed beneficial ownership of these securities except to the extent of his pecuniary interest.

On December 21, 2023, Mercer Street Global Opportunity Fund, LLC filed a Schedule 13G with the SEC, disclosing a significant stake in Biodexa Pharmaceuticals PLC. The fund reported ownership of 109,396,800 Ordinary Shares, which includes 46,900,000 shares issuable upon the exercise of warrants, representing a 9.99% ownership in the company. This stake is subject to a beneficial ownership blocker, preventing the fund from exercising warrants that would result in ownership exceeding 9.99% of Biodexa's outstanding Ordinary Shares. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Biodexa Pharmaceuticals. Jonathan Juchno, an authorized representative of Mercer Street Global Opportunity Fund, LLC, has disclaimed beneficial ownership of these securities except to the extent of his pecuniary interest.